ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
28. Oktober 2024 08:00 ET
|
ViaNautis Bio
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
28. Oktober 2024 03:00 ET
|
ViaNautis Bio
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
ViaNautis Appoints Ray Jupp as Chief Scientific Officer
21. Oktober 2024 02:00 ET
|
ViaNautis Bio
ViaNautis Appoints Ray Jupp as Chief Scientific Officer Cambridge, UK 21 October – ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of genetic...
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer
18. Oktober 2024 07:00 ET
|
ViaNautis Bio
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer Cambridge UK, 18 October 2024 – ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront...
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors
30. April 2024 07:00 ET
|
ViaNautis Bio
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors Co-Founder of Spark Therapeutics with over 20 years of industry experience to support ViaNautis Bio in its next...
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors
30. April 2024 02:00 ET
|
ViaNautis Bio
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors Co-Founder of Spark Therapeutics with over 20 years of industry experience to support ViaNautis Bio in its next...
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines
13. November 2023 02:00 ET
|
ViaNautis Bio
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver...